Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bottrop – page 77

1 691 clinical trials in Bottrop, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bottrop at a glance
1 691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 691 trials in Bottrop

Open in trial search

Study of Imetelstat in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Refractory to Erythropoiesis-Stimulating Agents

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imetelstat Sodium
  • Sponsor:Geron Corp.

Study on OM-85 for Preventing Respiratory Infections in Children with Wheezing Illness (Ages 6 Months to 5 Years)

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Sponsor:OM Pharma SA

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Evaluating Higher Dose Nusinersen in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Nusinersen
  • Sponsor:Biogen Idec Research Limited

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

B-cell lymphoma

Not recruiting

Study on Rituximab and Drug Combination for Treating Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Universitaetsklinikum Muenster AöR

Hodgkin's disease+1

Not recruiting

Study on the Safety and Effectiveness of GEN3017 for Patients with Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Genmab A/S

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride for Adults with Early-Stage Unfavorable Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:University Of Cologne

Hodgkin's disease

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:University Of Cologne

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Bladder cancer

Not recruiting

Study on the Effectiveness of Mistletoe Extract and Mitomycin in Patients with Superficial Bladder Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Abnoba GmbH

Study on Allogeneic Stem Cell Transplantation for Children and Adolescents with Acute Lymphoblastic Leukemia Using Etoposide, Treosulfan, and Thiotepa

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bottrop

What the registry says about research in the country

01 Breast Cancer Research

Extensive clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments, evaluating innovative therapeutic approaches.

  • Early-stage breast cancer treatments
  • Metastatic disease management
  • Targeted therapy combinations

Studies include evaluation of novel drugs like ribociclib, elacestrant, and olaparib in combination with endocrine therapy.

02 Triple Negative Breast Cancer

Research investigating immunotherapy combinations and novel treatment approaches for patients with triple-negative breast cancer.

  • Post-surgery treatment optimization
  • Combination therapy assessment
  • Survival outcome improvements

Clinical trials evaluating sacituzumab govitecan-hziy with pembrolizumab versus standard treatments.

03 Ovarian Cancer Studies

Investigations into treatment strategies for advanced ovarian cancer, including peritoneal and fallopian tube cancers.

  • First-line therapy optimization
  • Combined treatment approaches
  • Progressive disease management

Focus on evaluating niraparib and bevacizumab combinations following chemotherapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.